The estimated Net Worth of Pharmaceutical Co Ltd Takeda is at least 129 百万$ dollars as of 24 January 2024. Pharmaceutical Takeda owns over 3,703,703 units of Phathom Pharmaceuticals Inc stock worth over 70,229,402$ and over the last 3 years Pharmaceutical sold PHAT stock worth over 58,476,503$.
Pharmaceutical has made over 22 trades of the Phathom Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Pharmaceutical sold 3,703,703 units of PHAT stock worth 29,999,994$ on 24 January 2024.
The largest trade Pharmaceutical's ever made was selling 3,703,703 units of Phathom Pharmaceuticals Inc stock on 24 January 2024 worth over 29,999,994$. On average, Pharmaceutical trades about 223,474 units every 45 days since 2021. As of 24 January 2024 Pharmaceutical still owns at least 3,755,583 units of Phathom Pharmaceuticals Inc stock.
You can see the complete history of Pharmaceutical Takeda stock trades at the bottom of the page.
Pharmaceutical's mailing address filed with the SEC is 1-1, NIHONBASHI-HONCHO 2-CHOME, , CHUO-KU, TOKYO, M0, 103-8668.
Over the last 5 years, insiders at Phathom Pharmaceuticals Inc have traded over 112,538,769$ worth of Phathom Pharmaceuticals Inc stock and bought 2,393,679 units worth 45,337,731$ . The most active insiders traders include Capital Management, L.P.Ra ...、James N Topper、Pharmaceutical Co Ltd Takeda. On average, Phathom Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of 2,226,815$. The most recent stock trade was executed by Azmi Nabulsi on 15 July 2024, trading 10,901 units of PHAT stock currently worth 127,760$.
phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.
Phathom Pharmaceuticals Inc executives and other stock owners filed with the SEC include: